
Roche adds head to corporate executive committee
pharmafile | January 23, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | John Reed, Roche
Roche has announced that John Reed has been appointed as head of Roche Pharma Research and Early Development (pRED) and a member of the enlarged corporate executive committee.
Based in Basel he’ll be reporting to Severin Schwan, chief executive of the Roche Group and will assume his new role on 2 April. Mike Burgess who was the interim head of pRED, has decided to leave Roche to head up discovery for BMS.
Commenting on the appointment, Schwan said: “We are delighted to welcome John Reed to Roche, who has led one of the world’s top laboratory-based medical research institutes. With his broad scientific and medical background he is ideally positioned to drive Roche’s strategy of translating a better understanding of disease mechanisms into promising therapeutics.”
Prior to joining Roche Reed has been chief executive at Sanford-Burnham Medical Research Institute in La Jolla, California. Roche says he is one of the world’s leading biomedical researchers with a focus on cancer, neuroprotection, autoimmunity, and other diseases.
Reed added: “I am honoured to join the Roche organisation and continue the company’s superb legacy of developing innovative new medicines for patients in need.”
Related Content

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …






